CB: Tissue Resources and Molecular Pathology

CB：组织资源和分子病理学

• 批准号: 7921404
• 负责人: IGNACIO I. WISTUBA
• 金额: $ 25.84万
• 依托单位: UT SOUTHWESTERN MEDICAL CENTER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7921404
• 关键词: 3-Dimensional; Aliquot; Arts; Biological Markers; Blood specimen; Cancer Center; Cancer cell line; Cataloging; Catalogs; Cell Line; Cells; Clinical; Clinical Data; Collaborations; DNA; Data; Databases; Epithelial Cells; Funding; Human; Image; Image Analysis; Immunohistochemistry; In Situ; Institution; Lung; Malignant - descriptor; Malignant neoplasm of lung; Medical center; Methodology; Molecular; Non-Malignant; Paraffin; Pathologic; Pathologist; Pathology; Patients; Peer Review; Process; RNA; Reproduction spores; Research; Research Personnel; Resources; Site; Source; Specimen; Techniques; Texas; Tissue Microarray; Tissues; Translational Research; Tumor Cell Line; Universities; Xenograft procedure; anticancer research; base; c new; design; experience; innovation; molecular pathology; programs; tissue resource; tumor

SPORE Core B. Pathology and Tissue Resources Core. The Tissue Resources and Molecular Pathology Core will provide routine and innovative tissues and materials, as well as conventional and molecular pathology assistance, essential for achieving the aims of the SPORE projects. Routine materials include tumors and non-malignant lung specimens and tumor cell lines. Over 2,500 well-characterized tumors with annotated clinical data and 200 cell lines have been banked, and over 15,000 aliquots of tumor or cell line pellets, RNA or DNA or paraffin sections are available to SPORE investigators. State-of-art molecular pathology facilities devoted to lung cancer translational research directed by experienced lung cancer molecular pathologists are available. Our Aim 1 is to collect, process, store, catalog and distribute tissues, cells and blood specimens, both malignant and non-malignant, and relevant clinico-pathologic data, as requested by the various component projects of the SPORE program. Aim 2 is to develop and utilize innovative or routine tissue and cell resources that will aid in the successful completion of the SPORE program aims. Innovative materials include: a) cell pellets and tissue microarrays (TMAs) and high throughput image analysis of in situ techniques, b) new lung cancer cell lines and lung cancer xenografts made directly from patient specimens, c) new immortalized and non-immortalized human bronchial epithelial cells (HBECs) and 3-dimensional organotypic cultures. Aim 3 is to perform and interpret tissue-based molecular methodologies in close collaboration with the component projects of the SPORE program to satisfy their approved aims. This includes immunohistochemistry (IHC) information on over 90 lung cancer relevant biomarkers on the TMAs with information stored in an image database and integrated with the clinical annotations. Aim 4 is to promote collaboration among investigators in this SPORE, other lung cancer SPORES, other investigators in MD Anderson Cancer Center, UT Southwestern Medical Center, and other investigators nationally and internationally pursuing lung cancer relevant research. All of our five projects in this application will utilize CORE materials. Heavy utilization of our routine and innovative materials, and close interactions with the SPORE investigators will greatly aid the successful completion of the aims of our SPORE proposal. The SPORE Tissue Resource Core is designed and has operated as a facility receiving support from several other sources beyond SPORE funding including in a manner non-overlapping with other Cancer Center activities at both MD Anderson and UT Southwestern Medical Centers. This means that SPORE discoveries and data have far reaching beneficial effects across the range of lung cancer research conducted at these two institutions.

孢子核B.病理和组织资源核心。组织资源和分子 病理核心将提供常规和创新的组织和材料，以及常规和 分子病理学援助，对于实现孢子项目的目标至关重要。常规材料 包括肿瘤和非恶性肺标本和肿瘤细胞系。超过2500个特征良好的 带有带注释的临床数据和200个细胞系的肿瘤已被储存，超过15,000个等分试样的肿瘤 孢子研究人员可供选择，或细胞系颗粒，RNA或DNA或石蜡切片。最先进的 分子病理设施致力于经验丰富的肺部指导的肺癌转化研究 癌症分子病理学家可用。我们的目标1是收集，处理，存储，目录和分发 组织，细胞和血液标本，包括恶性和非恶性以及相关的临床病理数据， 按照孢子计划的各个组件项目的要求。目标2是开发和利用 创新或常规的组织和细胞资源，将有助于成功完成孢子 计划的目标。创新材料包括：a）细胞颗粒和组织微阵列（TMA）和高吞吐量 原位技术的图像分析，b）新的肺癌细胞系和肺癌异种移植物 直接从患者标本中，c）新的永生和非胎胎的人支气管上皮细胞 （HBEC）和三维器官型培养物。 AIM 3是执行和解释基于组织的分子 与孢子计划的组件项目密切合作的方法，以满足其 批准的目标。这包括有关90多个肺癌相关的免疫组织化学（IHC）信息 TMA上的生物标志物，其中存储在图像数据库中并与临床集成 注释。 AIM 4是促进该孢子中其他肺癌的研究人员之间的合作 孢子，MD Anderson癌症中心，UT西南医疗中心的其他调查人员以及其他 在国内和国际追求肺癌相关研究的研究者。我们的所有五个项目 该应用程序将利用核心材料。大量利用我们的日常材料和创新材料，以及 与孢子调查人员的密切互动将极大地帮助我们成功完成我们的目标 孢子建议。孢子组织资源核心的设计并已作为接收设施运行 除孢子资金以外的其他几个来源的支持，包括以不重叠的方式 MD Anderson和UT西南医疗中心的其他癌症中心活动。这意味着 在肺癌范围内，孢子的发现和数据具有远大的有益作用 在这两个机构进行的研究。